Author Photo
Written by:

FDA Issues New Abilify® Warning

| Read Time: < 1 minute

Cory Watson Attorneys is no longer accepting these cases.

The Food and Drug Administration (FDA) issued a new warning on May 3 that links the use of Aripiprazole (Abilify, Abilify Maintena, Aristada) with compulsive or uncontrollable urges such as binge eating, excessive shopping, gambling, and an increase in sex drive. Abilify users reported that these behaviors stopped when the medicine was discontinued or the dose was reduced.

According to the FDA safety announcement, “pathological gambling is listed as a reported side effect in the current aripiprazole drug labels, this description does not entirely reflect the nature of the impulse-control risk FDA identified. In addition, FDA has become aware of other compulsive behaviors associated with aripiprazole, such as compulsive eating, shopping, and sexual actions. These compulsive behaviors can affect anyone who is taking the medicine. As a result, FDA is adding new warnings about all of these compulsive behaviors to the drug labels and the patient Medication Guides for all aripiprazole products.”

This is the strongest FDA warning to date about the risks associated with the popular drug Abilify, prescribed to treat certain mental disorders, including schizophrenia, bipolar disorder, Tourette’s disorder, and irritability associated with autistic disorder.

There is help available for Abilify users who have suffered as a result of taking the drug. The experienced drug injury lawyers at Cory Watson Attorneys are representing hundreds of Abilify victims nationwide and are available for a free consultation. If you or a loved one has suffered while taking Abilify, call now at (877) 562-0000 or quickly fill out our online contact form.


Please consult with your doctor before stopping or changing any prescription medication.

  • Subscribe to Our Blog